Stocks · Healthcare · Medical - Devices
Bruker Corporation BRKR
$63.24 +2.10% Close, Oct 2, 2026 · NASDAQ · Market cap $9.63B
Strong trend
Next earnings report: Nov 2, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-0.70, down 234.4% year over year.
- Over the past year the stock returned +82.1%, ahead of the S&P 500 by 67.1 percentage points.
- Net debt is 7.0× EBITDA, a high level of leverage.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 33%
- EPS growth (TTM, YoY)Bottom 9%
- FCF growth (TTM, YoY)Top 18%
- Revenue growth, 3-year CAGRTop 49%
- Revenue growth accelerationTop 34%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 28%
- Gross marginBottom 31%
- Operating marginTop 37%
- Accruals (lower is better)Bottom 39%
- Net debt / EBITDA (lower is better)Bottom 10%
- Interest coverTop 33%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 32%
- Free-cash-flow yieldTop 32%
- EBITDA / enterprise valueTop 32%
- Sales / enterprise valueTop 42%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 26%
- 6-month returnTop 13%
- 1-year return vs S&P 500Top 19%
- Distance from 52-week highTop 7%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 17%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 17%
- Upside to consensus price targetBottom 10%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 25%
- Maximum drawdown, 3 yearsTop 48%
- Beta vs S&P 500 (lower is better)Bottom 47%
- Net debt / EBITDA (lower is better)Bottom 10%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 0.4% | 1.6% | ↑ |
| EPS growth (YoY) | -146.0% | -234.4% | ↓ |
| Gross margin | 48.3% | 46.7% | ↓ |
| Operating margin | 5.3% | 3.6% | ↓ |
| FCF margin | 1.4% | 2.7% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 1.6% | 0.4% | ↑ | Bottom 33% |
| EPS growth (TTM, YoY) | -234.4% | -146.0% | ↓ | Bottom 9% |
| Gross margin | 46.7% | 48.3% | ↓ | Bottom 31% |
| Operating margin | 3.6% | 5.3% | ↓ | Top 37% |
| Net margin | -2.0% | 2.3% | ↓ | — |
| Free-cash-flow margin | 2.7% | 1.4% | ↑ | — |
| Return on invested capital | 2.6% | — | Top 28% | |
| Revenue growth, 3-year CAGR | 10.7% | — | Top 49% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 0.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +16.9 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 6.99×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 2.9×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.34%
- Net buyback yield (TTM)
- 0.05%
- Shareholder yield
- 0.39%
- Share count change, 1 year
- +0.3%
- Share count change, 3-year CAGR
- +1.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +33.7%
- Average 2-day reaction, last 8
- -3.2%
- Positive 20 days after report
- 2 of 8
Analysts
- Consensus price target
- $63.60
- Target vs current price
- +0.6%
- Analysts with a rating
- 33
- Share rating Buy or Strong Buy
- 52%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | +27.3% | -21.8% | -12.4% | -9.8% | — |
| May 6, 2026 | +34.8% | +11.3% | +17.7% | +65.0% | +65.3% |
| Feb 12, 2026 | -9.2% | -11.6% | -8.6% | -17.4% | +4.1% |
| Nov 3, 2025 | +81.8% | -0.6% | +2.5% | +22.9% | +13.6% |
| Aug 4, 2025 | -3.0% | -8.6% | -19.9% | -10.6% | +1.7% |
| May 7, 2025 | +2.2% | +3.3% | -1.8% | -4.1% | -3.7% |
| Feb 13, 2025 | +1.3% | -1.0% | +2.5% | -12.9% | -27.4% |
| Nov 5, 2024 | -1.6% | +3.4% | -4.5% | -3.0% | -4.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | $0.49 | $0.38 | +27.3% | $838.5M |
| May 6, 2026 | $0.31 | $0.23 | +34.8% | $823.4M |
| Feb 12, 2026 | $0.59 | $0.65 | -9.2% | $977.2M |
| Nov 3, 2025 | $0.60 | $0.33 | +81.8% | $860.5M |
| Aug 4, 2025 | $0.32 | $0.33 | -3.0% | $797.4M |
| May 7, 2025 | $0.47 | $0.46 | +2.2% | $801.4M |
| Feb 13, 2025 | $0.76 | $0.75 | +1.3% | $979.6M |
| Nov 5, 2024 | $0.60 | $0.61 | -1.6% | $864.4M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (forward) | 29.8× | — | — | — |
| EV / EBITDA | 45.9× | — | — | Top 32% |
| EV / Sales | 3.25× | — | — | Top 42% |
| Free-cash-flow yield | 0.98% | — | — | Top 32% |
| Earnings yield | -1.11% | — | — | Top 32% |
P/E over the past five years
Range 25.7× – 78.4× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +82.1%
- Earnings per share growth (TTM)
- -234.4%
- Change in P/E multiple
- +129.1%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 13
- Days above the 200-day average
- 104
- 50-day average slope (20 days)
- +0.2%
- 200-day average slope (20 days)
- +2.8%
- Distance from 50-day average
- +7.4%
- Distance from 200-day average
- +28.3%
- RSI (14)
- 56.7
- Relative volume
- 0.97×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 72.4%
- Volatility vs own 5-year history
- 98th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.16
- Correlation with S&P 500
- 0.32
- Current drawdown from 1-year high
- -2.3%
- Maximum drawdown, 3 years
- -68.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 21, 2024 | Sep 3, 2025 | -68.9% | 363 days | Not yet recovered |
| Sep 3, 2021 | Sep 26, 2022 | -46.5% | 266 days | 363 days (Mar 7, 2024) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $9.63B
- EPS, diluted (TTM)
- -$0.70
- Revenue (TTM)
- $3.50B
- Dividend yield
- 0.32%
- 52-week range
- $32.37 – $66.98
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $2.42B | $2.53B | $2.96B | $3.37B | $3.44B |
| Gross profit | $1.21B | $1.31B | $1.51B | $1.65B | $1.58B |
| Operating income | $413.3M | $432.7M | $436.9M | $253.1M | $236.0M |
| Net income | $277.1M | $296.6M | $427.2M | $113.1M | -$8.6M |
| EPS (diluted) | $1.81 | $1.99 | $2.90 | $0.76 | -$0.15 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $864.4M | $979.6M | $801.4M | $797.4M | $860.5M | $977.2M | $823.4M | $838.5M |
| Net income | $40.9M | $13.7M | $17.4M | $7.6M | -$59.6M | $26.0M | $14.4M | -$52.0M |
| EPS (diluted) | $0.27 | $0.09 | $0.11 | $0.05 | -$0.41 | $0.10 | $0.02 | -$0.41 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $282.4M | $274.4M | $350.1M | $251.3M | $134.1M |
| Capital expenditure | -$92.0M | -$129.2M | -$106.9M | -$115.3M | -$120.2M |
| Free cash flow | $190.4M | $145.2M | $243.2M | $136.0M | $13.9M |
| Dividends paid | -$24.2M | -$29.8M | -$29.4M | -$30.2M | -$22.8M |
| Net share buybacks | -$146.3M | -$260.3M | -$142.8M | $403.0M | $659.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $184.9M
- Total assets
- $6.05B
- Total liabilities
- $3.63B
- Total debt
- $1.92B
- Net debt
- $1.73B
- Shareholders’ equity
- $2.40B
As of Jun 30, 2026 (filed Aug 5, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Sep 21, 2026 | $0.05 | Oct 7, 2026 |
| Jun 22, 2026 | $0.05 | Jul 7, 2026 |
| Mar 23, 2026 | $0.05 | Apr 7, 2026 |
| Dec 8, 2025 | $0.05 | Jan 2, 2026 |
| Sep 23, 2025 | $0.05 | Oct 3, 2025 |
| Jun 16, 2025 | $0.05 | Jun 27, 2025 |
| Mar 17, 2025 | $0.05 | Mar 28, 2025 |
| Dec 2, 2024 | $0.05 | Dec 16, 2024 |
Short interest
- Shares sold short
- 12,490,387
- Days to cover
- 6.30
- Change vs previous report
- +4.0%
FINRA short interest, settlement date Sep 15, 2026.